The Neurolyser XR
The Neurolyser XR is a pioneering High Intensity Focused Ultrasound (HIFU) system developed to offer a non-invasive alternative for the thermal ablation of neural tissue at the bone-tissue interface. This device is specifically engineered to target the lumbar medial branch nerves, providing an effective solution for patients suffering from chronic back pain due to lumbar zygapophyseal joint syndrome.
Non-invasive procedure: Eliminates the need for surgical incisions and reduces the risk of infection.
Precise targeting: Advanced imaging and targeting ensure accurate ablation of the medial branch nerves.
Reduced recovery time: Patients experience faster recovery and less post-procedural pain.
Lower risk of complications: Minimizes common complications associated with invasive procedures, such as bleeding and infection.
The Neurolyser XR harnesses the power of HIFU technology to deliver precise, controlled thermal energy to the targeted nerves. Unlike traditional methods, the Neurolyser XR ensures minimal damage to surrounding tissues, thanks to its real-time imaging and targeting capabilities. This significantly reduces procedural risks and recovery times, making it a superior choice compared to traditional radiofrequency ablation (RFA).
Key benefits of the Neurolyser XR include:
Technology and Benefits
The Neurolyser XR harnesses the power of HIFU technology to deliver precise, controlled thermal energy to the targeted nerves. Unlike traditional methods, the Neurolyser XR ensures minimal damage to surrounding tissues, thanks to its real-time imaging and targeting capabilities. This significantly reduces procedural risks and recovery times, making it a superior choice compared to traditional radiofrequency ablation (RFA).
Key benefits of the Neurolyser XR include:
Clinical Evidence
This graph was taken from the first paper (Fluoroscopy-guided high-intensity focused ultrasound neurotomy of the lumbar zygapophyseal joints: a prospective, open-label study)
Extensive clinical research supports the efficacy and safety of the Neurolyser XR system. In a recent prospective study, the Neurolyser XR demonstrated remarkable results, with 82.6% of patients reporting significant pain relief at 6 months post-procedure. These findings are consistent with traditional RFA outcomes but with fewer side effects and complications. The Neurolyser XR offers a promising alternative for clinicians seeking to enhance patient care with innovative, non-invasive technology.
This graph was taken from the first paper (Fluoroscopy-guided high-intensity focused ultrasound neurotomy of the lumbar zygapophyseal joints: a prospective, open-label study)
Extensive clinical research supports the efficacy and safety of the Neurolyser XR system. In a recent prospective study, the Neurolyser XR demonstrated remarkable results, with 82.6% of patients reporting significant pain relief at 6 months post-procedure. These findings are consistent with traditional RFA outcomes but with fewer side effects and complications. The Neurolyser XR offers a promising alternative for clinicians seeking to enhance patient care with innovative, non-invasive technology.